Home
ZBIO
ZBIO News

Latest ZENAS BIOPHARMA INC (ZBIO) News on June 26, 2025

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 days ago

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma to Present at the Jefferies Global Healthcare Conference

GlobeNewswire

a month ago

Zenas BioPharma to Present at the Jefferies Global Healthcare Conference

Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates

GlobeNewswire

a month ago

Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Zenas BioPharma Insiders US$407k Short Of Breakeven On Stock Purchase

Simply Wall St.

2 months ago

Zenas BioPharma Insiders US$407k Short Of Breakeven On Stock Purchase

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

GlobeNewswire

3 months ago

Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress

Benzinga

3 months ago

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress

MT Newswires

3 months ago

Wedbush Initiates Zenas BioPharma at Outperform With $35 Price Target

Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

GlobeNewswire

3 months ago

Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

Is Zenas BioPharma (NASDAQ:ZBIO) In A Good Position To Invest In Growth?

Simply Wall St.

3 months ago

Is Zenas BioPharma (NASDAQ:ZBIO) In A Good Position To Invest In Growth?

Argus Research

4 months ago

Daily – Vickers Top Buyers & Sellers for 02/20/2025

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

GlobeNewswire

5 months ago

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

MT Newswires

5 months ago

Wolfe Research Initiates Coverage on Zenas BioPharma With Outperform Rating, $19 Price Target

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

GlobeNewswire

5 months ago

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

Zenas BioPharma initiated with a Buy at H.C. Wainwright

TipRanks

6 months ago

Zenas BioPharma initiated with a Buy at H.C. Wainwright

MT Newswires

6 months ago

HC Wainwright Initiates Zenas BioPharma at Buy With $30 Price Target

Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley

TipRanks

6 months ago

Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley

Argus Research

7 months ago

Daily – Vickers Top Buyers & Sellers for 12/05/2024

Argus Research

7 months ago

Daily – Vickers Top Buyers & Sellers for 11/21/2024

Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire

7 months ago

Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

GlobeNewswire

7 months ago

Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences

GlobeNewswire

8 months ago

Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences

Opening Day: Another trio of biotech IPOs make Friday debut

TipRanks

8 months ago

Opening Day: Another trio of biotech IPOs make Friday debut

Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering

GlobeNewswire

9 months ago

Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering

Share on Social Networks: